518342-58-0

Basic information

• Product Name: Benzenamine, 2-fluoro-4-[(trimethylsilyl)ethynyl]-
• CAS NO: 518342-58-0
• Molecular Formula: C11H14FNSi
• Molecular Weight: 207.323
• Mol File: 518342-58-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-fluoro-4-[(trimethylsilyl)ethynyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-fluoro-4-[(trimethylsilyl)ethynyl]-(518342-58-0)
• EPA Substance Registry System: Benzenamine, 2-fluoro-4-[(trimethylsilyl)ethynyl]-(518342-58-0)

Safety Data

• Hazardous Substances Data: 518342-58-0(Hazardous Substances Data)

Upstream product

• 29632-74-4 2-fluro-4-iodoaniline 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 568599-39-3 3,4-difluoro-2-[[2-fluoro-4(trimethylsilylethynyl)phenyl]amino]benzoic Acid 
• 1008112-39-7 4-ethynyl-2-fluoroaniline 
• 518342-64-8 (3-fluoro-4-iodophenylethynyl)trimethylsilane 
• 518342-83-1 [4-(3-fluoro-4-phenylethynylphenylethynyl)-3-trifluoromethylphenylethynyl]trimethylsilane 
• 518342-91-1 [3-fluoro-4-(4-phenylethynyl-3-trifluoromethylphenylethynyl)phenylethynyl]-trimethylsilane 
• 518342-86-4 5-(2-fluoro-4-trimethylsilanylethynylphenylethynyl)-2-phenylethynyl-benzonitrile 
• 518342-81-9 [3-fluoro-4-(3-fluoro-4-phenylethynylphenylethynyl)phenylethynyl]-trimethylsilane 
• 518342-82-0 2-(3-fluoro-4-phenylethynylphenylethynyl)-5-trimethylsilanylethynyl-benzonitrile 
• 518342-96-6 [4-(3-ethyl-4-phenylethynylphenylethynyl)-3-fluorophenylethynyl]trimethylsilane 

Relevant articles and documents

LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents

Herein we report a scaffold-hopping approach to identify a new scaffold with a zinc binding headgroup. Structural information was used to give novel oxazolidinone-based LpxC inhibitors. In particular, the most potent compound, 23j, showed a low efflux ratio, nanomolar potencies against E. coli LpxC enzyme, and excellent antibacterial activity against E. coli and K. pneumoniae. Computational docking was used to predict the interaction between 23j and E. coli LpxC, suggesting that the interactions with C207 and C63 contribute to the strong activity. These results provide new insights into the design of next-generation LpxC inhibitors.

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.